These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 34656974)
1. Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Joshi Yalta K; Ozkan U; Yalta T Heart; 2021 Dec; 107(23):1922. PubMed ID: 34656974 [No Abstract] [Full Text] [Related]
2. Response to: Correspondence on "Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure" by Yalta Joshi SS; Singh T; Singh J; Newby DE Heart; 2021 Dec; 107(23):1922-1923. PubMed ID: 34656972 [No Abstract] [Full Text] [Related]
3. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure. Patoulias D; Papadopoulos C; Doumas M J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683 [No Abstract] [Full Text] [Related]
4. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. Khan MS; Butler J; Greene SJ Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728 [No Abstract] [Full Text] [Related]
5. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF. Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089 [No Abstract] [Full Text] [Related]
7. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881 [No Abstract] [Full Text] [Related]
8. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys. Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Liang B; Liang Y; Gu N BMC Cardiovasc Disord; 2022 Jun; 22(1):261. PubMed ID: 35689186 [TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news! Katsiki N; Rizzo M; Mikhailidis DP J Diabetes Complications; 2023 Jul; 37(7):108510. PubMed ID: 37235924 [No Abstract] [Full Text] [Related]
11. Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection? Khouri MG; Greene SJ JACC Heart Fail; 2022 Aug; 10(8):568-570. PubMed ID: 35902160 [No Abstract] [Full Text] [Related]
12. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials. Liang B; Gu N Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809 [TBL] [Abstract][Full Text] [Related]